For the Inventor, By the Inventor

Enter assignee name

Calgary, Canada

Resverlogix Corporation

Calculating rank

USPTO Granted Patents = 23

% Expired Patents = 30.4

CIPO Patents = 2

EPO Patents = 13

Trademarks = 1

Forward Citations = 298

Loading Chart...

Loading Chart...

25 inventors (with patents filed for the assignee):

Henrik C Hansen (17 out of 18 patents)

Norman C W Wong (5 out of 5 patents)

Fabrizio S Chiacchia (5 out of 5 patents)

4. David Robert McCaffrey (4 out of 5 patents)

5. Joseph E L Tucker (4 out of 4 patents)

6. Ewelina B Kulikowski (3 out of 3 patents)

7. Dean E Gilham (2 out of 2 patents)

8. Sylwia Wasiak (2 out of 2 patents)

9. Christopher R A Halliday (2 out of 2 patents)

10. Narmada R Shenoy (2 out of 6 patents)

11. Aziz Naeem Khan (2 out of 2 patents)

12. Christopher Ross Armstrong Halliday (2 out of 5 patents)

13. Kenneth Eugene Lebioda (2 out of 5 patents)

14. Jan Johansson (1 out of 9 patents)

15. Gregory Steven Wagner (1 out of 18 patents)

23 patents: Sort by Forward Citations

1. 12673059 - Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor (2026-07-07),

2. 12551484 - Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor (2026-02-17),

3. 11407719 - Anti-inflammatory agents (2022-08-09),

4. 10882828 - Anti-inflammatory agents (2021-01-05),

5. 10772894 - Compositions and therapeutic methods for the treatment of complement-associated diseases (2020-09-15),

6. 10532054 - Compounds for the prevention and treatment of cardiovascular diseases (2020-01-14),

7. 10131640 - Anti-inflammatory agents (2018-11-20),

8. 10111885 - Compositions and therapeutic methods for the treatment of complement-associated diseases (2018-10-30),

9. 10016426 - Pharmaceutical compositions for substituted quinazolinones (2018-07-10),

10. 9757368 - Anti-inflammatory agents (2017-09-12),

11. 9610251 - Pharmaceutical compositions for substituted quinazolinones (2017-04-04),

12. 9238640 - Anti-inflammatory agents (2016-01-19),

13. 9199990 - Compounds for the prevention and treatment of cardiovascular diseases (2015-12-01),

14. 8952021 - Compounds for the prevention and treatment of cardiovascular disease (2015-02-10),

15. 8889698 - Compounds for the prevention and treatment of cardiovascular diseases (2014-11-18),

Company Overview

Resverlogix Corporation, based in Calgary, Canada, is a biotechnology company focused on developing innovative therapies for chronic diseases. The organization specializes in epigenetics and aims to address significant unmet medical needs through its research and development efforts. Resverlogix is particularly known for its work in cardiovascular health and related conditions, leveraging advanced scientific insights to create potential treatments that could improve patient outcomes and quality of life.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

23 Patents

#45 in Calgary

#634 in Canada

#27,736 in the World

Calgary, Canada

Resverlogix Corporation

Forward Citations = 298

25 inventors:

Henrik C Hansen (17 out of 18 patents)

Norman C W Wong (5 out of 5 patents)

Fabrizio S Chiacchia (5 out of 5 patents)

4. David Robert McCaffrey (4 out of 5 patents)

5. Joseph E L Tucker (4 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Resverlogix Corporation. Retrieved from https://idiyas.com/company/resverlogix

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…